<p>Asian American, Black, and Hispanic populations underrepresented compared with U.S. population demographics</p>

Sample sizes, primary end points, interpretations mainly concordant for studies published on <em>medRxiv</em>, then in journals

Individuals who were independently aware of the FDA decision demonstrated reduced willingness to participate

Article describes inadequate oversight relating to development of COVID-19 vaccines and predating the pandemic

Those with a family history or higher self-perceived risk are more likely to participate

Findings include exclusion of people with cognitive, visual, hearing, mobility, and other disabilities, without documented justification

Gap seen in cardiovascular, psychiatry, and cancer trial participation versus national prevalence disease data

Trial was the first to test a drug meant to delay or halt mental decline in people who have a genetic predisposition

Extrapolation of the findings from pivotal clinical trials to the approved indication most common for disease severity

<p>No improvement seen in representation of Black patients after implementation of a 2015 FDA action plan to improve diversity</p>